Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Vibostolimab |
Synonyms | |
Therapy Description |
Vibostolimab (MK-7684) acts as an antagonist to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) by preventing the interaction of TIGIT with its ligands, NECTIN2 (CD112) and PVR (CD155), potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Vibostolimab | MK7684|MK 7684|MK-7684 | Immune Checkpoint Inhibitor 149 TIGIT Antibody 19 | Vibostolimab (MK-7684) acts as an antagonist to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) by preventing the interaction of TIGIT with its ligands, NECTIN2 (CD112) and PVR (CD155), potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02964013 | Phase I | Vibostolimab Pembrolizumab + Vibostolimab | Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) | Completed | 0 |